Red_Block.jpgEvestra_Logo_with_caption.jpgClean_EvestraLogo_2012.jpgClean_EvestraLogo_2012.jpg Maika_and_girl.jpgMonika_cycling.jpgBindu_reaching.jpg Green_Color.jpgdsgn_1423_pic6.jpgdsgn_1423_pic3.jpgMain_Menu_Button_blue.jpg dsgn_1423_pic3.jpgdsgn_1423_pic3.jpg

Board of Directors and Observers

Mr. Kerr was Interim President of Texas Biomedical Research Institute (formerly SFBR) from June of 2006 until 2008 and served as Chairman of the TX Biomed Board of Trustees from 1998 until June of 2007. Since 1992, he has been active in venture capital investment in the life sciences, as an early-stage investor, either personally or through a managed fund, or board member in a number of drug development ventures including BioNumerik Pharmaceuticals, Inc., ILEX Oncology, Brava Therapeutics and Azaya Therapeutics, Inc., where he also serves as chairman. In the 1980s, Mr. Kerr served as Chairman and CEO of American Century Corp., a New York Stock Exchange-listed financial services company, and previously was a partner with the Houston law firm Andrews & Kurth and the San Antonio firm Cox & Smith. Mr. Kerr received his B.A. from Stanford University and his J.D. from The University of Texas School of Law.

John C. Kerr



Mr. Lingnau has been a management leader in the pharmaceutical industry for more than 35 years, beginning with his term as General Manager of the Schering Guatemala City plant in Central America during the 1970s. At Schering, he moved from the Guatemala City installation to Marketing Manager in Bogota, to Worldwide Marketing and Sales in Berlin. From Schering, Mr. Lingnau accepted the position of Director of Business Development at Berlex Laboratories, eventually taking on the role of President, and has been Chairman since 1985.  Returning to Schering in 1985, he became Head of Worldwide Sales and Marketing of Schering AG’s Pharmaceutical Division in Berlin and then President and CEO of Schering Berlin, Inc., eventually becoming a member of the Schering Executive Board of Directors, Vice Chairman of Schering Berlin, Inc. and a member of the Board of Directors of PhRMA.  In addition to serving as advisor to the Evestra Board, Mr. Lingnau is currently on the Board of Directors of Nektar Therapeutics (San Carlos, CA),  and is a member of the Advisory Group for RSVP Group (Wiesbaden, Germany).

Lutz Lingnau


Blue_Board_sub_menu.png dsgn_1423_pic3.jpg

Dr. Shaked has extensive managerial and pharmaceutical product development experience in commercializing biologics and conventional drugs. Before co-founding Evestra, he was President and CEO of Spherics, Inc. Prior to Spherics, as former President of ILEX Products, Inc. and Chief Operating Officer of ILEX Oncology, Inc., he helped to reshape the product pipeline and led the product development team. He has held a number of senior R&D and corporate management positions: ImmuLogic Pharmaceutical Corp., Berlex Biosciences, Inc., Triton Biosciences, Inc., CODON Corp. and Chiron Corp. He obtained his Ph.D. in organic and applied biochemistry from MIT.

Ze’ev Shaked, Ph.D.


Dr. Nickisch enjoyed more than 28 years of experience with Schering AG in a wide range of positions before the acquisition of Schering by Bayer. He joined Schering AG as a medicinal chemist and worked on various steroid research projects for five years. He moved from research to development and headed the chemical development function for a number of years. He then moved into project management and led numerous projects in oncology and female health. Dr. Nickisch then joined the business unit Specialized Therapeutics at Berlex as head of project and portfolio management and was promoted to the head of global project management. He completed his studies at the Technical University Berlin with a Ph.D. in organic chemistry.

Klaus Nickisch, Ph.D.


Evestra's Board of Directors currently consists of Dr. Shaked, Dr. Nickisch, Árpád Götze and two members of the Texas Biomedical Research Institute Board of Trustees John C. Kerr and Richard T. Schlosberg.  In addition to the board members, Evestra’s board includes one observer Mr. Lutz Lingnau.

Dick Schlosberg is the former Publisher and CEO of the Los Angeles Times and the current Chair of the Board of the Texas Biomedical Research Institute. He is the immediate past President and CEO of the David and Lucile Packard Foundation, one of the nation’s largest philanthropic foundations. Additionally, Mr. Schlosberg is a board member of eBay, Inc, Edison International and the Kaiser Family Foundation. He is a founding director of the Bank of San Antonio and the United States Air Force Academy Endowment, a charitable foundation supporting the Air Force Academy. He serves on the board of the San Antonio Area Foundation and the San Antonio Medical Foundation. Schlosberg graduated from the United States Air Force Academy and earned a master’s degree with honors from the Harvard Business School. He served five years as an Air Force pilot and is a veteran of the Vietnam War. He and his wife, Kathy, have two grown children and four grandchildren, all living in San Antonio.

Richard T.


Schlosberg III

© 2017 Evestra, Inc.


Mr. Götze has 32 years of experience in the pharmaceutical industry. Since 1998 he has held the position of Director of Business Development at Gedeon Richter Plc., Hungary, and is a Director of Preglem SA, the Swiss based affiliate of Richter. Mr. Götze joined Gedeon Richter in 1990 as Head of the API Export Department, and later became Director of International Sales. After that he served four years as head of Richter's affiliate in Spain. From 1983 to 1990 he worked with Medimpex, the Hungarian international trading company for pharmaceuticals. Mr. Götze graduated as an economist from the Budapest University of Economics in 1983.


Árpád Götze